Nanobiotix Jumps on Positive Early-Stage Data for Melanoma
JNJ-1900 offers new hope for advanced melanoma patients whose cancer progressed after many treatments, including anti-PD-1. Injected into tumors, activated by radiation, then combined with anti-PD-1, it shows promising early safety and efficacy signals, potentially boosting the immune system.